Overview

Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy

Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Evaluating the Optimal Effective Dose and Safety of Conbercept in Treating Retinopathy of Prematurity (ROP)
Phase:
NA
Details
Lead Sponsor:
Wang Yusheng
Treatments:
KH902 fusion protein